Intravascular Imaging-guided Percutaneous Coronary Intervention in Patients With and Without Diabetes: A Meta-analysis of Randomized Trials.

Can J CardiolMar 17, 2026 (epub)
Clinical ResearchCardiology

Hendrianus Hendrianus, Sang Yeub Lee, Hoyoun Won et al.

✦ AI-curated · Sources linked

In 30 seconds

This meta-analysis pooled 11 randomized controlled trials (n = 17,692) comparing intravascular imaging-guided with angiography-guided PCI, with outcomes assessed by diabetes status. The primary outcome was target vessel failure (TVF) at ≥ 1 year. Imaging-guided PCI was associated with lower TVF in patients with diabetes (RR 0.69, 95% CI 0.53-0.90) and without diabetes (RR 0.65, 95% CI 0.55-0.77); there was no evidence that the effect differed by diabetes status (P interaction = 0.72).

Key findings

  • In patients with diabetes, imaging-guided PCI reduced TVF versus angiography guidance (RR 0.69, 95% CI 0.53-0.90; P = 0.006).
  • In patients without diabetes, imaging-guided PCI reduced TVF (RR 0.65, 95% CI 0.55-0.77; P < 0.001).
  • The effect did not differ significantly by diabetes status (P interaction = 0.72).
  • Exploratory head-to-head analyses found no difference in TVF risk between OCT and IVUS, with consistent findings across diabetes status.

Why it matters

The findings suggest that the reduction in TVF associated with intravascular imaging-guided PCI is not confined to patients with or without diabetes. This supports considering diabetes status alongside other clinical and procedural factors rather than assuming it changes the relative benefit of imaging guidance. Subgroup estimates for complex PCI in diabetes were imprecise.

What to keep in mind

The meta-analysis combines trials with different imaging approaches and PCI populations; estimates for some diabetic subgroups were imprecise. Meta-regression identified age and follow-up duration as potential effect modifiers in patients with diabetes.

Source

Published in Can J Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.